Company Overview of Juventas Therapeutics, Inc.
Juventas Therapeutics, Inc. discovers and develops biopharmaceutical therapies for regenerative medicine. It offers Stromal Derived Factor-1, a therapy that improves cardiac function, as well as enables to protect and repair tissues following organ–damage in pre–clinical disease models. The company also develops biopharmaceuticals that activate the natural repair process that occurs after an injury. In addition, it provides therapies for wound healing and peripheral vascular diseases. Juventas Therapeutics, Inc. was formerly known as AcelleRX Therapeutics, Inc. and changed its name to Juventas Therapeutics, Inc. in April 2009. The company was founded in 2007 and is based in Cleveland, Ohio.
10265 Carnegie Avenue
Cleveland, OH 44106-2130
Founded in 2007
Key Executives for Juventas Therapeutics, Inc.
Senior Vice President of Finance & Operations
Compensation as of Fiscal Year 2014.
Juventas Therapeutics, Inc. Key Developments
Juventas Therapeutics, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 10:30 AM
Nov 20 14
Juventas Therapeutics, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 10:30 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
Juventas Therapeutics Presents Phase II Clinical Study Results at 2014 American Heart Association Scientific Sessions
Nov 12 14
Juventas Therapeutics Inc. announced that investigators will present results from two independent clinical trials that show JVS-100, a non-viral gene therapy expressing stromal cell-derived factor 1 (SDF-1), improves clinical status of patients with critical limb ischemia (CLI) and symptomatic ischemic heart failure at the American Heart Association Scientific Sessions 2014 on Nov. 17 in Chicago, Ill. JVS-100, Juventas' lead development asset, has been shown to promote tissue repair in multiple indications through activation of natural regenerative repair pathways. The findings from two randomized placebo controlled trials, STOP-CLI, testing JVS-100 in patients with critical limb ischemia, and STOP-HF, testing JVS-100 in patients with advanced heart failure, highlight the safety and potential efficacy of Juventas' novel gene therapy strategy.
Juventas Therapeutics Appoints Troy Ignelzi as Senior Vice President of Finance and Operations
Oct 28 14
Juventas Therapeutics announced that Troy Ignelzi has joined the company as Senior Vice President of Finance and Operations. Troy brings 20 years in finance, operations, and business development experience with start-up and established life sciences companies. Mr. Ignelzi joins Juventas from YES Pharmaceuticals where he was Sr. Vice President of Business Development. In addition to global business development, he was responsible for financing engagements and provided strategic guidance to multiple clients' SEC filings and subsequent successful IPOs.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|